In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

eFFECTOR Therapeutics Inc.

www.effector.com

Latest From eFFECTOR Therapeutics Inc.

Pipeline Watch: Phase III Starts With Bavencio, MultiStem And VT-1161

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment

Venture Capital Edition: Pfizer deprioritized neuroscience as an early R&D focus earlier this year, but will stay involved by spending 25% of the $600m added to its venture fund on neurology investments. Also, China VC investment keeps up fast pace and Alta Partners closes a new $130m health care fund.

Financing StartUps and SMEs

Biopharma Quarterly Deal-Making Statistics, Q2 2017

Biopharma companies raised $13.4 billion in Q2, mostly through IPOs. Thanks to several billion-dollar deals in Q2, 2017 is shaping up to be a year of CRO consolidations. Big pharma continued divesting assets to smaller biopharma companies.

BioPharmaceutical Deals

eFFECTOR Translates $38.6m Into Five Cancer Clinical Trials

The firm's $38.6m in Series C cash will fund additional clinical trials for lead translation regulator eFT508, support the first human trial for eFT226 and advance a third program into preclinical studies.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • eFFECTOR Therapeutics Inc.
  • Senior Management
  • Steve Worland, PhD, Pres. & CEO
    Alana McNulty, CFO
    Siegfried Reich, PhD, SVP, Research
    Jeremy Barton, MD, CMO
    Annette Matthies, PhD, VP, Corp. Dev.
  • Contact Info
  • eFFECTOR Therapeutics Inc.
    Phone: (858) 925-8215
    11180 Roselle St.
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register